Research, Collaboration, Grant and License Agreements - Additional Information (Details)		1 Months Ended				2 Months Ended	3 Months Ended	12 Months Ended
	Oct. 29, 2020 USD ($)	Oct. 31, 2020 USD ($)	Aug. 31, 2020 USD ($)	Apr. 30, 2020 USD ($) Product	Dec. 31, 2019 USD ($) $ / shares shares	Nov. 30, 2020 USD ($)	Dec. 31, 2019 USD ($) $ / shares shares	Dec. 31, 2020 USD ($) shares	Jun. 30, 2020 $ / shares	Mar. 31, 2020 shares	Feb. 21, 2020 USD ($)	Nov. 30, 2019 shares
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Common stock, shares issued | shares					10,894,999		10,894,999	37,761,435
Stock price per share | $ / shares									$ 7.52
Research and development							$ 987,000	$ 31,893,000
UT Southwestern Agreement
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Preclinical activities period under sponsored research agreements				2 years
Minimum licensed product to develop obtain regulatory approval for and commercialize | Product				1
Common stock, shares issued | shares										0		2,179,000
Percentage of fully diluted common stock shares outstanding												20.00%
Percentage of entitled to receive additional shares on fully diluted basis												10.00%
UT Southwestern Agreement | Discount for Lack of Marketability
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Measurement input					20		20
UT Southwestern Agreement | Common Stock
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Share issued an increase to common stock and additional paid in capital							$ 980,000
Stock price per share | $ / shares					$ 0.45		$ 0.45
Queen's Agreement
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Research grant of committed fund amount					$ 3,800,000
Percentage of interest rate					6.00%		6.00%
Research grant outstanding fund amount								0
Queen's Agreement | Research and Development Expense
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Cash payment to acquire license agreement				$ 3,000,000
Queen's Agreement | Maximum
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
License agreement regulatory milestones payment											$ 10,000,000
License agreement commercial milestones payment											$ 10,000,000
Abeona CLN1 Agreements
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
License fee payment			$ 3,000,000
Purchase of clinical materials and reimbursement incurred development costs		$ 4,000,000
Research and development								7,000,000
License fee								$ 3,000,000
Abeona CLN1 Agreements | Maximum
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
License and inventory purchase agreement regulatory related milestones payment			26,000,000
License and inventory purchase agreement sales related milestones payment			$ 30,000,000
Abeona | Abeona Rett Agreement
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Payment of one-time upfront license fee	$ 3,000,000
Abeona | Maximum | Abeona Rett Agreement
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Regulatory related milestones obligation payable	26,500,000
Sale-related milestones per licensed product and royalties on net sales of licensed products payable	$ 30,000,000
Catalent Agreements
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Payment of upfront project initiation fee						$ 2,000,000